Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide, affecting an estimated 33, 60 million people. It occurs when the atria fire chaotic electrical signals instead of beating in a coordinated rhythm, producing an irregular and often rapid heartbeat. AF carries a fivefold increased stroke risk, doubles the risk of dementia and all-cause mortality, and significantly reduces quality of life.
This article covers AF causes, classification, recurrence, and the full range of treatments recommended by the 2024 ESC and 2023 ACC/AHA guidelines.
This article is for general information only. Always consult a qualified cardiologist regarding your specific situation.
Causes and Symptoms
What Causes Atrial Fibrillation?
AF arises from structural and electrophysiological changes in the atria. The most common causes:
Cardiac: • Hypertension (most common modifiable risk factor) • Heart failure and reduced left ventricular ejection fraction • Coronary artery disease and myocardial infarction • Valvular heart disease (especially mitral valve disorders) • Congenital heart disease
Non-cardiac: • Obstructive sleep apnea • Thyroid disorders (especially hyperthyroidism) • Obesity and diabetes • Excessive alcohol consumption (holiday heart syndrome) • Physical inactivity or extreme endurance exercise • Pulmonary embolism or chronic lung disease
Symptoms: • Palpitations or irregular heartbeat • Shortness of breath, especially on exertion • Fatigue and reduced exercise tolerance • Dizziness or lightheadedness • Chest discomfort or pressure
Note: AF is asymptomatic in a significant proportion of patients, making ECG-based screening essential, particularly in individuals over 65.
Types of Atrial Fibrillation
Classification of AF
| Type | Definition | Key Feature |
|---|---|---|
| Paroxysmal AF | Self-terminating within 7 days | Most common; often resolves within 48 hours |
| Persistent AF | Lasts more than 7 days; requires cardioversion | Does not self-terminate |
| Long-standing persistent AF | Continuous for more than 12 months | May still respond to rhythm control |
| Permanent AF | Accepted as ongoing by patient and clinician | Rate control only |
| Subclinical AF | Device-detected; no recognized episodes | Stroke risk still debated |
The 2023 ACC/AHA guidelines introduced a staging system (Stage 1, 4) mapping disease progression from risk factors to permanent AF, underscoring the value of early intervention.
Diagnosis
How Is AF Diagnosed?
ECG: The gold standard, absent P waves and irregular RR intervals confirm AF.
Holter monitoring: 24-hour to 14-day continuous ECG to detect paroxysmal AF missed on a resting ECG.
Implantable loop recorders (ILRs): Long-term monitoring for patients with cryptogenic stroke or suspected but uncaptured AF.
Wearables and smartwatches: Consumer-grade screening shown to improve AF detection rates in older adults (GUARD AF trial, 2024).
Echocardiography: Evaluates structural heart disease, left atrial size, ventricular function, and valvular pathology.
Laboratory tests: TSH, CBC, renal function, coagulation screen, BNP/NT-proBNP if heart failure is suspected.
CHA₂DS₂-VASc score: Annual stroke risk calculator. Score ≥2 (men) or ≥3 (women) indicates anticoagulation is recommended.
Treatment
How Is AF Treated?
The 2024 ESC AF-CARE framework organises management into four pillars:
[C] Comorbidity and risk factor management The first and most impactful step. Weight loss, blood pressure control, sleep apnea treatment, alcohol reduction, and physical activity all reduce AF burden and recurrence risk.
[A] Avoid stroke DOACs (direct oral anticoagulants) are preferred over warfarin for non-valvular AF. Antiplatelet agents alone are not an acceptable substitute.
[R] Rate and rhythm control
Rate control: Target resting heart rate below 110 bpm using beta-blockers, calcium channel blockers (verapamil, diltiazem), or digoxin.
Rhythm control: Restore and maintain sinus rhythm via: • Electrical cardioversion (DC cardioversion) • Pharmacological cardioversion (flecainide, propafenone, amiodarone) • Long-term antiarrhythmic drug therapy • Catheter ablation, pulmonary vein isolation (PVI): recommended for symptomatic patients who fail antiarrhythmic drugs; increasingly considered first-line. Pulsed-field ablation (PFA) is an emerging technique with favourable safety data (MANIFEST-17K, 2024, n=17,600+).
[E] Evaluate and reassess AF is a lifelong condition. Treatment plans must be reassessed as symptoms, stroke risk, and disease progression evolve.
Both guidelines emphasise that early rhythm control is associated with better long-term outcomes and should not be deferred unnecessarily.
Multisystem Impact
How AF Affects the Body
Stroke: Blood pooling in the left atrial appendage can clot and embolise to the brain. AF-related strokes are typically more severe and disabling than other stroke types.
Heart failure: Persistent uncontrolled tachycardia causes tachycardia-induced cardiomyopathy, a reversible form of ventricular dysfunction that improves with rate or rhythm control.
Dementia: AF confers roughly a twofold increased risk, likely through microembolic events, chronic cerebral hypoperfusion, and inflammation.
Renal impairment: AF and chronic kidney disease share risk factors and worsen each other. DOAC dosing must be adjusted for renal function.
Mental health: AF is associated with anxiety, depression, and significant reduction in daily functioning, particularly in patients with frequent or prolonged episodes.
Warning Signs
When AF Becomes an Emergency
Call emergency services immediately (101 Israel / 911 US / 112 Europe) if you experience:
- Sudden severe chest pain or pressure, possible acute coronary syndrome
- Stroke signs (FAST): facial drooping, arm weakness, slurred speech
- Very rapid heart rate (>150 bpm) with hypotension, dizziness, or loss of consciousness
- Acute severe breathlessness at rest, possible pulmonary oedema
- Sudden vision loss, severe headache, or new neurological symptoms
- Syncope (fainting) in a patient with known AF
When to See a Doctor
When to Seek Medical Attention
Consult a cardiologist or GP promptly if you notice:
- Palpitations lasting more than a few minutes, or recurring frequently
- A first-ever episode of irregular heartbeat, even if it resolved on its own
- Unexplained worsening fatigue or reduced exercise tolerance
- Recurring dizziness associated with palpitations
- Any change in frequency, severity, or duration of episodes (if already diagnosed)
- Unusual bruising, blood in urine or stools, or unexplained headaches (if taking anticoagulants)
Early referral is especially important for younger patients, those with reversible triggers, and candidates for catheter ablation, early rhythm control yields better long-term outcomes.
Practical Tips
Lifestyle and Self-Management
Weight management: Sustained weight loss of 10% or more significantly reduces AF burden and recurrence.
Alcohol reduction: Even moderate excess (above 21 units/week) triples the risk of progression from paroxysmal to persistent AF. Reduction or abstinence is recommended.
Blood pressure control: Keeping BP below 130/80 mmHg reduces both AF burden and stroke risk.
Physical activity: Moderate aerobic exercise (150 min/week) improves outcomes. Extreme endurance sports are associated with increased AF risk, discuss with your cardiologist.
Sleep apnea treatment: CPAP therapy significantly reduces AF recurrence in patients with obstructive sleep apnea.
Medication adherence: Never stop anticoagulation without cardiologist advice, subclinical AF may persist without symptoms.
Symptom diary: Tracking episode timing, duration, and triggers helps guide clinical decision-making.
FAQ
What is atrial fibrillation?
AF is the most common sustained cardiac arrhythmia. Instead of contracting at 60, 100 bpm, the atria fire chaotically at 300, 600 impulses per minute. The AV node filters these, but the ventricular response remains irregular, producing an irregular pulse. AF raises stroke risk fivefold, doubles dementia risk, and is diagnosed by ECG showing absent P waves and irregular RR intervals.
Is atrial fibrillation dangerous?
Yes, but severity depends on AF type, structural heart disease, and whether treatment is initiated. The primary danger is cardioembolic stroke from clots forming in the left atrial appendage. AF-related strokes are typically more severe than other types. It also doubles dementia and mortality risk and can cause heart failure through persistent tachycardia. With appropriate anticoagulation, rate or rhythm control, and risk factor management, most patients live active, full lives.
Can AF be a one-time event?
Yes, a single isolated episode can occur, often triggered by reversible causes such as alcohol, fever, hyperthyroidism, or surgery. However, roughly 25% of paroxysmal AF patients develop persistent or chronic AF within 1, 3 years, and about one in three progresses within 10 years. Even a single episode warrants cardiology evaluation, ECG documentation, CHA₂DS₂-VASc scoring, and trigger assessment.
What is recurrent AF?
Two or more documented episodes, the most common pattern. Recurrent paroxysmal AF can progress to persistent AF, especially with hypertension, heart failure, valvular disease, or untreated sleep apnea. AF burden (total time in AF) is a stronger predictor of stroke and mortality than episode count. The AF-CARE framework prioritises comorbidity and lifestyle management to prevent recurrence.
How is AF treated?
Per AF-CARE: (1) comorbidity management, weight, BP, alcohol, sleep apnea; (2) stroke prevention with DOACs; (3) rate control with beta-blockers, calcium channel blockers, or digoxin (target <110 bpm); (4) rhythm control with cardioversion, antiarrhythmic drugs, or catheter ablation (PVI). Ablation is recommended for symptomatic patients failing drugs and is increasingly first-line in suitable patients. Early rhythm control is associated with better long-term outcomes.
What medications are used for AF?
Four categories: (1) Anticoagulants, DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) preferred over warfarin for non-valvular AF; warfarin for mechanical valves. (2) Rate-control agents, beta-blockers (metoprolol, bisoprolol), calcium channel blockers (diltiazem, verapamil, avoid in HFrEF), digoxin. (3) Antiarrhythmic drugs, flecainide and propafenone (structurally normal hearts only), amiodarone (most effective; significant toxicity profile), sotalol, dronedarone. (4) Upstream therapies, ACE inhibitors, ARBs, statins to modify the atrial substrate in patients with hypertension or heart failure.
Summary
Atrial fibrillation is a common, potentially serious arrhythmia requiring lifelong, personalised management. The 2024 ESC AF-CARE framework and 2023 ACC/AHA staging system reflect a shift toward early, holistic intervention, addressing root causes alongside arrhythmia-specific treatment.
If you have been diagnosed with AF or experienced unexplained palpitations, the key steps are: seek a cardiology evaluation, document with ECG, assess and reduce stroke risk, address modifiable triggers, and discuss whether rate control, rhythm control, or catheter ablation best fits your profile. With optimal management, most AF patients achieve excellent symptom control, significantly reduced stroke risk, and a normal life expectancy.
Be the first to comment!